{"id":"iv-golimumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections (including serious infections)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Tuberculosis reactivation risk"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking TNF-α, golimumab reduces the inflammatory cascade that drives autoimmune and inflammatory diseases. TNF-α is a central mediator of inflammation in conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The IV formulation allows for systemic delivery and rapid onset of action in moderate to severe inflammatory conditions.","oneSentence":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:26.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Ulcerative colitis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT02277444","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-22","conditions":"Arthritis, Juvenile","enrollment":130},{"nctId":"NCT03733925","phase":"PHASE4","title":"A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2019-01-07","conditions":"Spondylitis, Ankylosing, Arthritis, Psoriatic","enrollment":100},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT03253796","phase":"PHASE4","title":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-07","conditions":"Spondyloarthritis","enrollment":323},{"nctId":"NCT02728934","phase":"","title":"Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-02-25","conditions":"Arthritis, Rheumatoid","enrollment":1279},{"nctId":"NCT01362153","phase":"PHASE1","title":"A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2007-12-26","conditions":"Rheumatoid Arthritis","enrollment":49},{"nctId":"NCT00975130","phase":"PHASE3","title":"Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Arthritis, Rheumatoid","enrollment":3366},{"nctId":"NCT01962974","phase":"PHASE3","title":"A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)","status":"TERMINATED","sponsor":"Janssen Biotech, Inc.","startDate":"2013-10","conditions":"Arthritis, Rheumatoid","enrollment":7},{"nctId":"NCT02390700","phase":"","title":"Observational Study of Golimumab Intravenous Infusion","status":"TERMINATED","sponsor":"Janssen Inc.","startDate":"2015-02","conditions":"Rheumatoid Arthritis","enrollment":78},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00361335","phase":"PHASE3","title":"A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2006-09","conditions":"Rheumatoid Arthritis","enrollment":643},{"nctId":"NCT00488774","phase":"PHASE2, PHASE3","title":"An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2007-08","conditions":"Colitis, Ulcerative","enrollment":291}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SCH 900259, intravenous"],"phase":"phase_3","status":"active","brandName":"IV golimumab","genericName":"IV golimumab","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"Golimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), a key inflammatory cytokine. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}